- Arcturus Therapeutics : Barclays cuts to underweight from equal-weight, price target to $25 from $33
- BT Group: New Street upgraded from buy to neutral.
- FIGS : BofA Securities starts at buy with $42 price target
- Flywire : Goldman Sachs starts at buy with $53 price target
- GlaxoSmithKline: Barclays confirms its negative recommendation, keeping its Sell rating. The target price remains set at GBp 1250
- HSBC: UBS maintains a Neutral rating. The target price remains set at GBp 450.
- Intel : Citigroup adjusts price target to $60 from $65, maintains neutral rating
- Ocado: Morgan Stanley upgraded from Overweight to Overweight targeting GBp 2825.
- Paymentus : Goldman Sachs starts coverage at buy with $54 price target
- ResMed : Needham adjusts price target to $267 from $229, buy rating kept
- Rio Tinto: UBS upgrades from neutral to sell.
- Singular Genomics : Goldman Sachs starts coverage at buy with $35 price target
- SSE: Jefferies upgrades its Buy rating to Hold with a target of GBP 1680.
- Sykes Enterprises, Incorporated : Baird downgrades stock to neutral from outperform; price target remains $54